Understanding how different cancer vaccines affect T cell responses

Evaluating the impact of antigen selection on T cell responses to therapeutic cancer vaccination

NIH-funded research Harvard Medical School · NIH-11042696

This study is looking at how choosing certain pieces of cancer cells for vaccines can help boost the immune response in patients, with the goal of creating better and more personalized cancer treatments.

Quick facts

Grant typeFellowship grant
Study typeNIH-funded research
Funding institutionHarvard Medical School NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-11042696 on NIH RePORTER

What this research studies

This research investigates how selecting specific antigens for cancer vaccines can influence the immune response of T cells in patients. By examining the effects of various tumor antigens, including those derived from mutations, the study aims to uncover the mechanisms behind T cell activation and response to these vaccines. The approach includes characterizing T cell responses in a controlled setting, which may help optimize vaccine strategies for better patient outcomes. The findings could lead to more effective cancer immunotherapies tailored to individual patient needs.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancer who are considering or currently undergoing immunotherapy treatments.

Not a fit: Patients with early-stage cancer who have not yet started any form of treatment may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective cancer vaccines that enhance the immune system's ability to fight tumors.

How similar studies have performed: Previous studies have shown promising results with antigen-specific cancer vaccines, indicating potential for success in this approach.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-canceranti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.